2024-07-23 10:28:05 ET
Summary
- Johnson & Johnson might be the worst performing big pharma stock YTD, but there's upside possible for it in the remainder of 2024.
- Revenue growth guidance was upgraded and even with a downgrade in EPS guidance, the number is still expected to see a YoY increase.
- Its market multiples indicate the possibility of some uptick, and there are dividends to consider too.
- JNJ isn't without its risk, due to Stelara's patent expirations and litigation against it, but for now, it's a safer stock than not.
Among the big five pharmaceutical stocks by market capitalisation, Johnson & Johnson ( JNJ ) has been the worst performer year-to-date [YTD]. While the rest of them have all seen at least some uptick, it’s actually down slightly (see chart below)....
Read the full article on Seeking Alpha
For further details see:
4 Positives For Johnson & Johnson